Abstracts tagged "Fatigue"

Abstract Number: 2042 • ACR Convergence 2022
Sjögren’s Disease and Mitochondrial Function
Biji T Kurien¹, Pharaoh Gavin², Joshua Cavett¹, Valerie Lewis³, Ambre Chambers¹, Bhaskaran Shylesh⁴, Anjum Juvaria¹, Brittany Karfonta¹, Lida Radfar¹, Astrid Rasmussen⁴, Christopher Lessard⁴, Darise Farris⁴, Kathy Sivils⁵, Kristi A Koelsch⁴, Holly Van Remmen⁴ and R. Hal Scofield¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Washington, Seattle, WA, ³Veterans Affairs Medical Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Sjögren's disease (SjD) is a chronic inflammatory, autoimmune disorder with reduced lacrimal/salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia, respectively. Also, SjD patients…
Abstract Number: 0127 • ACR Convergence 2022
The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function
Aleksander Lenert¹, Robyn Domsic², Karmela Kim Chan³, Melissa Oliver⁴, Jisna Paul⁵, Courtney Kremer⁶, Emma Leisinger¹, Svjetlana Dolovcak⁷, Sandy D. Hong⁸, Aruni Jayatilleke⁹, Petar Lenert⁷, T. Shawn Sato¹, Samir Shah¹⁰, Shima Yasin¹¹, Yongdong (Dan) Zhao¹², Daniel Solomon¹³, Jonathan Templin¹ and Polly Ferguson¹¹, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³Hospital for Special Surgery, New York, NY, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Ohio State University Hospital, Dublin, OH, ⁶University of Iowa Stead Family Children's Hospital, Solna, IA, ⁷University of Iowa Hospitals and Clinics, Iowa City, IA, ⁸University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁹Temple University, PHILADELPHIA, PA, ¹⁰Tufts Medical Center, Boston, MA, ¹¹University of Iowa Carver College of Medicine, Iowa City, IA, ¹²University of Washington, Redmond, WA, ¹³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) and disease impact are important to adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO) but remain poorly described. Patient-reported…
Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Jennifer Rogers¹, Amanda Eudy², Roberta Alexander³, David Pisetsky⁴, John Conklin³, Kai Sun⁵, Lisa Criscione-Schreiber⁶, Jayanth Doss⁵, Rebecca Sadun⁵, Mithu Maheswaranathan¹ and Megan Clowse⁵, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Exagen, Inc., Vista, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…
Abstract Number: 0204 • ACR Convergence 2022
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
Jessica Leung¹, Claire Owen², David Liew³ and Russell Buchanan³, ¹Austin Health, Preston, Victoria, Australia, ²Austin Health, Malvern East, Australia, ³Austin Health, Heidelberg, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients…
Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Dafna Gladman¹, Michael Starr², Roberto Ranza³, Ana-Maria Bravo Perdomo⁴, Marcie Strauss⁵, May Shawi⁶, Chenglong Han⁷, Emmanouil Rampakakis⁸, Andrew Ostor⁹ and Philip J Mease¹⁰, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Montreal General Hospital, Montréal, QC, Canada, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, ⁵Medasource, Indianapolis, IN, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹Cabrini Medical Centre, Monash University & Emeritus Research, Melbourne, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…
Abstract Number: 0369 • ACR Convergence 2022
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Paul Kamudoni¹, Alexandra Lauer¹, Oliver Guenther¹, Cristina Vazquez Mateo² and Karon Cook³, ¹the healthcare business of Merck KGaA, Darmstadt, Germany, ²Global Clinical Development, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ³Feral Scholars, Broaddus, TX
Background/Purpose: Fatigue is among the most prevalent symptoms of systemic lupus erythematosus (SLE) and is associated with patient distress, work dysfunction, and worse overall health…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 0315 • ACR Convergence 2021
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Samantha Wratten¹, Natasha Griffiths², Carl Cooper², Jessica Flynn², Rebecca Hall³, Linda Abetz-Webb², Wolfgang Hueber⁴, Briana Ndife⁵ and Pushpendra Goswami⁴, ¹Adelphi Values, Macclesfield, United Kingdom, ²Adelphi Values, Bollington, United Kingdom, ³Adelphi Values Ltd, Bollington, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis, East Hanover, NJ
Background/Purpose: The aim of this study was to gain qualitative patient feedback on the appropriateness of two Patient Reported Outcome (PRO) measures as assessments of…
Abstract Number: 0462 • ACR Convergence 2021
Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Eva-Maria Bachmair¹, Kathryn Martin Remmes¹, Lorna Aucott¹, Emma Dures², Richard Emsley³, Stuart Gray⁴, Elizabeth Kidd⁵, Vinod Kumar⁶, Karina Lovell⁷, Graeme MacLennan¹, Paul McNamee¹, John Norrie⁸, Lorna Paul⁹, Jon Packham¹⁰, Stuart Ralston¹¹, Stefan Siebert⁴, Alison Wearden⁷, Gary Macfarlane¹² and Neil Basu⁴, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of West of England, Bristol, United Kingdom, ³King's College London, London, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶NHS Tayside, Dundee, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, ⁸Usher Institute – University of Edinburgh, Edinburgh, United Kingdom, ⁹Glasgow Caledonian University, Glasgow, Scotland, United Kingdom, ¹⁰Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, United Kingdom, ¹¹University of Edinburgh, Edinburgh, Scotland, United Kingdom, ¹²Epidemiology Group, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, Scotland, United Kingdom
Background/Purpose: Inflammatory rheumatic disease (IRD) related fatigue is pervasive and disabling, even in otherwise stable disease. Although cognitive-behavioural approaches (CBAs) and personalised exercise programmes (PEP)…
Abstract Number: 0655 • ACR Convergence 2021
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Rosa Morlà¹, Beatriz Frade-Sosa², Núria Sapena³, Roberto Gumucio², Raimon Sanmarti² and Jose A Gomez-Puerta², ¹Hospital Universitari Clinic de Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
Abstract Number: 0717 • ACR Convergence 2021
Association of Fatigue with Disease Activity in Myositis
Tissa Bijoy George¹, Anjana Chandrasekhara Pillai², Siamak Moghadam-Kia³, Nicole Neiman⁴, Dana Ascherman³, Chester Oddis³, Dianxu Ren⁴ and Rohit Aggarwal³, ¹UPMC McKeesport, Monroeville, PA, ²UPMC, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The Idiopathic inflammatory myopathies are a heterogeneous group of rare systemic autoimmune diseases with muscle as the primary target. Fatigue is one of the…
Abstract Number: 0854 • ACR Convergence 2021
Confirmatory Factor Analysis of the Fatigue Assessment Instrument and Fatigue Severity Scale in Systemic Sclerosis
Alyssa Choi¹, Chelsea Rapoport², Erin Merz³, Marka Lyons⁴, Maureen Mayes⁵, Shervin Assassi⁶ and Vanessa Malcarne⁷, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, La Jolla, CA, ³Department of Psychology, California State University, Dominguez Hills, Carson, CA, ⁴Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶University of Texas McGovern Medical School at Houston, Houston, TX, ⁷SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA
Background/Purpose: Fatigue is a prevalent, debilitating symptom across chronic diseases that is difficult to treat and negatively impacts patients' quality of life. Patients with rheumatologic…
Abstract Number: 0860 • ACR Convergence 2021
Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis
Laura Kimble¹, Arezou Khosroshahi¹, Glenna Brewster¹, Nicole Carlson¹, Ronald Eldridge¹ and Elizabeth Corwin², ¹Emory University, Atlanta, GA, ²Columbia University, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) occurs predominantly in women and Black women have disproportionately poorer health outcomes across the trajectory of their disease compared to…
Abstract Number: 1150 • ACR Convergence 2021
Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)
Janet Poole¹, Deirdre Connolly² and Kristine Carandang³, ¹University of New Mexico, Albuquerque, NM, ²Trinity Centre for Health Sciences, Dublin, Ireland, ³Independent, San Diego, CA
Background/Purpose: Fatigue remains an understudied symptom of systemic sclerosis (SSc). For other diagnoses, increasing the use of energy conservation strategies, especially pacing. has been associated…
Abstract Number: 1235 • ACR Convergence 2021
Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Bruno Fautrel¹, Bochao Jia², Jianmin Wu³, Ju Ji², Julie Birt², Ewa Haladyj² and Tsutomu Takeuchi⁴, ¹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianaplolis, IN, ⁴Div. Rheumatology, Keio University, Tokyo, Japan
Background/Purpose: Fatigue is very common in rheumatoid arthritis (RA) and impairs patient quality of life. Baricitinib (BARI) improved fatigue, pain and other patient-reported outcomes (PROs)…

« Previous Page
1
…
3
4
5
6
7
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.